Monitoring bypassing agent therapy - a prospective crossover study comparing thromboelastometry and thrombin generation assay

Haemophilia

Volumn 21, Issue 2, 2015, Pages 275-283

  Tran, H T T ^a,b   Sorensen B ^c   Bjornsen S ^a   Pripp, A H ^a   Tjonnfjord G E ^a,b   Andre Holme, P ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c ALNYLAM PHARMACEUTICALS   (United States)

Author keywords

aPCC; Haemophilia A; Inhibitors; rFVIIa; ROTEM; TGA

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; ALLOANTIBODY; BLOOD CLOTTING FACTOR 8;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG INFUSION; HEMATOLOGICAL PROCEDURE; HEMATOLOGY ANALYZER; HEMOPHILIA A; HUMAN; INTERMETHOD COMPARISON; MIDDLE AGED; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBIN GENERATION ASSAY; THROMBOELASTOGRAPH; THROMBOELASTOGRAPHY; TREATMENT RESPONSE; YOUNG ADULT; BIOSYNTHESIS; BLOOD; BLOOD CLOTTING TEST; CASE CONTROL STUDY; IMMUNOLOGY; MALE;

ADULT; BLOOD COAGULATION TESTS; CASE-CONTROL STUDIES; CROSS-OVER STUDIES; FACTOR VIII; HEMOPHILIA A; HUMANS; ISOANTIBODIES; MALE; MIDDLE AGED; THROMBELASTOGRAPHY; THROMBIN; YOUNG ADULT;

EID: 84922980244     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12570     Document Type: Article

References (44)

1. Iorio A, Skinner MW, Makris M. Factor VIII products and inhibitors in severe hemophilia A. N Engl J Med 2013; 368: 1456.
2. Gouw SC, van den Berg HM, Fischer K et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood 2013; 121: 4046-55.
3. Eckhardt CL, van Velzen AS, Peters M et al. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood 2013; 122: 1954-62.
4. Oldenburg J, Goudemand J, Valentino L et al. Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin-free method] demonstrates efficacy, safety and low-risk for immunogenicity in routine clinical practice. Haemophilia 2010; 16: 866-77.
5. Astermark J, Donfield SM, DiMichele DM et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109: 546-51.
6. Birschmann I, Klamroth R, Eichler H, Schenk J, Kirchmaier CM, Halimeh S. Results of the WIRK prospective, non-interventional observational study of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disorders. Haemophilia 2013; 19: 679-85.
7. Shibeko AM, Woodle SA, Lee TK, Ovanesov MV. Unifying the mechanism of recombinant FVIIa action: dose dependence is regulated differently by tissue factor and phospholipids. Blood 2012; 120: 891-9.
8. Hoffman M. Platelet binding and activity of recombinant factor VIIa. Thromb Res. 2010; 125 Suppl 1: 6-8.
9. van't Veer C, Golden NJ, Mann KG. Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIa. Blood 2000; 95: 1330-5.
10. Gallistl S, Cvirn G, Leschnik B, Muntean W. Respective roles of factors II, VII, IX, and X in the procoagulant activity of FEIBA. Blood Coagul Fibrinolysis 2002; 13: 653-5.
11. ®: mode of action. Haemophilia 2004; 10: 3-9.
12. Turecek P, Schwarz HP. FEIBA: mode of action. Haemophilia 2004; 10 Suppl 2: 3-9.
13. Hilgartner MW, Knatterud GL. The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood 1983; 61: 36-40.
14. Sjamsoedin LJ, Heijnen L, Mauser-Bunschoten EP et al. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. N Engl J Med 1981; 305: 717-21.
15. Young G, Shafer FE, Rojas P, Seremetis S. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia 2008; 14: 287-94.
16. Berntorp E. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors. Haemophilia 2009; 15: 3-10.
17. Valentino LA, Allen GF, Gill JC et al. Case studies in the management of refractory bleeding in patients with haemophilia A and inhibitors. Haemophilia 2013; 19: 151-66.
18. Young G, Sorensen B, Dargaud Y, Negrier C, Brummel-Ziedins K, Key NS. Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives. Blood 2013; 121: 1944-50.
19. Nair SC, Dargaud Y, Chitlur M, Srivastava A. Tests of global haemostasis and their applications in bleeding disorders. Haemophilia 2010; 16(Suppl. 5): 85-92.
20. Wegner J, Popovsky MA. Clinical utility of thromboelastography: one size does not fit all. Semin Thromb Hemost 2010; 36: 699-706.
21. Salvagno GL, Berntorp E. Thrombin generation testing for monitoring hemophilia treatment: a clinical perspective. Semin Thromb Hemost 2010; 36: 780-90.
22. Bosch Y, Al Dieri R, ten Cate H et al. Preoperative thrombin generation is predictive for the risk of blood loss after cardiac surgery: a research article. J Cardiothorac Surg 2013; 8: 154.
23. Figueiredo S, Vigue B, Benhamou D, Duranteau J. Emergency reversal of heparin overdose in a neurosurgical patient guided by thromboelastography. Br J Anaesth 2013; 111: 303-4.
24. Napolitano LM, Cohen MJ, Cotton BA, Schreiber MA, Moore EE. Tranexamic acid in trauma: how should we use it? J Trauma Acute Care Surg 2013; 74: 1575-86.
25. Niebler RA, Gill JC, Brabant CP et al. Thromboelastography in the assessment of bleeding following surgery for congenital heart disease. World J Pediatr Congenit Heart Surg 2012; 3: 433-8.
26. Theusinger OM, Schroder CM, Eismon J et al. The influence of laboratory coagulation tests and clotting factor levels on Rotation Thromboelastometry (ROTEM(R)) during major surgery with hemorrhage. Anesth Analg 2013; 117: 314-21.
27. Hron G, Kollars M, Binder BR, Eichinger S, Kyrle PA. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA 2006; 296: 397-402.
28. Besser M, Baglin C, Luddington R, van Hylckama Vlieg A, Baglin T. High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study. J Thromb Haemost 2008; 6: 1720-5.
29. Dargaud Y, Beguin S, Lienhart A et al. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost 2005; 93: 475-80.
30. Whiting D, DiNardo JA. TEG and ROTEM: technology and clinical applications. Am J Hematol 2014; 89: 228-32.
31. Young G, Blain R, Nakagawa P, Nugent DJ. Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography. Haemophilia 2006; 12: 598-604.
32. Young G, Ebbesen LS, Viuff D et al. Evaluation of thromboelastography for monitoring recombinant activated factor VII ex vivo in haemophilia A and B patients with inhibitors: a multicentre trial. Blood Coagul Fibrinolysis 2008; 19: 276-82.
33. Sorensen B, Ingerslev J. Tailoring haemostatic treatment to patient requirements - an update on monitoring haemostatic response using thrombelastography. Haemophilia 2005; 11(Suppl. 1): 1-6.
34. Sorensen B, Ingerslev J. A direct thrombin inhibitor studied by dynamic whole blood clot formation. Haemostatic response to ex-vivo addition of recombinant factor VIIa or activated prothrombin complex concentrate. Thromb Haemost 2006; 96: 446-53.
35. Dargaud Y, Lienhart A, Negrier C. Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery. Blood 2010; 116: 5734-7.
36. Negrier C, Dargaud Y, Bordet JC. Basic aspects of bypassing agents. Haemophilia 2006; 12(Suppl. 6): 48-52; discussion -3.
37. Sorensen B, Johansen P, Christiansen K, Woelke M, Ingerslev J. Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation. J Thromb Haemost 2003; 1: 551-8.
38. Foley JH, Butenas S, Mann KG, Brummel-Ziedins KE. Measuring the mechanical properties of blood clots formed via the tissue factor pathway of coagulation. Anal Biochem 2012; 422: 46-51.
39. Young G, Zhang R, Miller R, Yassin D, Nugent DJ. Comparison of kaolin and tissue factor activated thromboelastography in haemophilia. Haemophilia 2010; 16: 518-24.
40. Luddington R, Baglin T. Clinical measurement of thrombin generation by calibrated automated thrombography requires contact factor inhibition. J Thromb Haemost 2004; 2: 1954-9.
41. Spronk HM, Dielis AW, Panova-Noeva M et al. Monitoring thrombin generation: is addition of corn trypsin inhibitor needed? Thromb Haemost 2009; 101: 1156-62.
42. van Veen JJ, Gatt A, Cooper PC, Kitchen S, Bowyer AE, Makris M. Corn trypsin inhibitor in fluorogenic thrombin-generation measurements is only necessary at low tissue factor concentrations and influences the relationship between factor VIII coagulant activity and thrombogram parameters. Blood Coagul Fibrinolysis 2008; 19: 183-9.
43. Brenni M, Worn M, Bruesch M, Spahn DR, Ganter MT. Successful rotational thromboelastometry-guided treatment of traumatic haemorrhage, hyperfibrinolysis and coagulopathy. Acta Anaesthesiol Scand 2010; 54: 111-7.
44. Rangarajan S, Austin S, Goddard NJ et al. Consensus recommendations for the use of FEIBA((R)) in haemophilia A patients with inhibitors undergoing elective orthopaedic and non-orthopaedic surgery. Haemophilia 2013; 19: 294-303.